Emergent BioSolutions Inc
Emergent BioSolutions Inc/ US29089Q1058 /
EBS
|
2024-04-17 9:59:55 PM
|
Chg.
-0.03
|
Volume |
Bid- |
Ask- |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
1.91USD
|
-1.55%
|
15,416
Turnover: 29,456.02 |
-Bid Size: - |
-Ask Size: - |
99.19 mill.USD |
- |
- |
Business description
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life.
Management board & Supervisory board
| CEO |
| Robert G. Kramer |
| Management board |
| Richard S. Lindahl, Adam R. Havey, Atul Saran, Dr. Karen L. Smith, Fuad El-Hibri, Katy Strei |
| Supervisory board |
| Fuad El-Hibri, Dr. Jerome M. Hauer, Dr. Kathryn C. Zoon, Dr. Zsolt Harsanyi, General George A. Joulwan, Louis W. Sullivan, Marvin White, Robert G. Kramer, Sr., Ronald B. Richard |
Company data
| Name: |
Emergent Biosolutions Inc. |
| Address: |
400 Professional Drive,Gaithersburg , Maryland 20879, USA |
| Phone: |
+1-301-795-1800 |
| Fax: |
+1-301-795-1899 |
| E-mail: |
-
|
| Internet: |
www.emergentbiosolutions.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12-31 |
| Free Float: |
75.10% |
| IPO date: |
- |
Investor relations
| Name: |
Robert G. Burrows |
| IR phone: |
+1-240-631-3280 |
| IR Fax: |
- |
| IR e-mail: |
BurrowsR@ebsi.com
|
Main Shareholders
| Freefloat |
|
75.10% |
| BlackRock, Inc. |
|
10.00% |
| Vanguard Group, Inc. |
|
8.90% |
| Neuberger Berman entities |
|
6.00% |
